HK Stock Market Move | METIS TECHBIO-P(07666) rose more than 6%, achieving a pre-clinical TCE authorization cooperation worth 1.6 billion US dollars, setting a single record in China.

Metis TechBio-P (07666) rose more than 6%, reaching 5.78% at the time of publication, closing at 14.28 Hong Kong dollars, with a turnover of 3.2111 million Hong Kong dollars. On the news front, recently, Jitai Technology announced its first major achievement in a strategic alliance with Deerfield Management, a global leading health investment and innovation platform, to accelerate the global development of next-generation immunotherapy. Jitai Technology has reached a global exclusive license agreement with Boulevard Bio, a US biotechnology company under Deerfield. As a result, Jitai Technology will receive an initial payment of 20 million US dollars, and will be eligible to receive up to a maximum of 1.6 billion US dollars in development, registration, and commercialization milestone payments, plus tiered sales royalties based on product sales. According to publicly disclosed information, this transaction sets a new record for the single largest overseas licensing transaction amount for a Chinese pharmaceutical company's preclinical TCE project, and it is also an important milestone for the internationalization of innovative Chinese AI drug delivery technology. Jitai Technology's self-developed NanoForge has achieved deep integration of AI protein design, delivery system development, and innovative therapy development, gaining dual validation from top global capital and industry partners, signaling that the AI-driven drug delivery platform is transitioning from the early-stage technology verification phase to the global commercial value realization phase.